CIRM Funded Clinical Trials

MSC engineered to produce BDNF for the treatment of Huntington's disease

Vicki Wheelock
Disease Area: 
CIRM Grant:
DR2A-05415 (Closed)
Award Value:
Trial Sponsor:
University of California, Davis
Trial Stage: 
Phase 1/2
Trial Status: 
Targeted Enrollment:
29 ID:

A team at UC Davis plans to use bone marrow derived mesenchymal stem cells to deliver a growth factor, called BDNF, to patients’ brains in order to reduce the death of nerve cells that occurs in Huntington’s Disease (HD). In preparation for such a clinical trial study, the team completed a CIRM-funded observational trial in a group of HD patients to study the progression of disease.


This trial is completed.